Inventisbio Co., Ltd

This study compares a new oral drug, D-0502, to a standard injected drug (fulvestrant) in people with a common type of advanced breast cancer (ER-positive, HER2-negative). The goal is to see if D-0502 can delay cancer growth better than the current treatment. About 640 adults who…

This study tests a new oral drug, D-2570, in 477 adults with moderate to severe plaque psoriasis. Participants will receive either D-2570, a placebo, or an active comparator to see how well it clears skin and improves quality of life. The trial is double-blind, meaning neither pa…

This study tests whether the experimental drug D-2570 can safely control symptoms in people with active systemic lupus erythematosus (SLE). About 120 adults with moderate-to-severe lupus will receive either D-2570 or a placebo, and researchers will measure how many achieve a mean…

This study tests an experimental drug called D-2570 in people with active psoriatic arthritis, a condition causing joint pain and swelling. About 222 adults aged 18 to 70 will receive either D-2570 or a placebo to see if the drug reduces joint tenderness and swelling. The main go…

This study tests an experimental drug called D-2570 against a placebo in 390 adults with moderate to severe plaque psoriasis. The main goal is to see if D-2570 can clear at least 90% of skin plaques after 16 weeks of treatment. Participants must have stable psoriasis for 6 months…